Ugo Ben-Nwauzor’s Post

🌍 Shaping the Future of Pharmaceutical Compounding in Africa! Looking forward to be part of an unparalleled nexus bringing together practitioners, visionaries, regulators, pioneers, and financiers—a collective dedicated to advancing pharmaceutical compounding across the continent. ✨ This is more than an event—it's a movement toward innovation, collaboration, and impactful change. 💡 Let’s lead the way in shaping tomorrow's compounding practices. #CompoundingPharmacy #InnovationInHealthcare #PharmaceuticalAdvancement

#Pharmaceuticas The Ethiopian Pharmaceutical Supply Service (EPSS) is on the brink of having a new mandate that could address the country's long-standing issues with medical supply shortages. A proposed directive seeks to shift the authority for pharmaceutical procurements from the Public Procurement & Property Authority to the EPSS. The change is expected to expedite critical decision-making, ensuring a more reliable supply of essential drugs to over 420 hospitals, 4,100 health centres, and 18,500 health posts nationwide. Read more https://ow.ly/WH8850UncZa

𝗧𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝗚𝗹𝗼𝗯𝗮𝗹 𝗜𝗻𝘀𝗶𝗱𝗲𝗿 𝗼𝗳 𝟮𝟬𝟮𝟱 𝗶𝘀 𝗵𝗲𝗿𝗲! 🌍 This month, we spotlight Logenix’s pivotal role in managing cold chain and pharmaceutical logistics in Guinea-Bissau. Don't miss out on future insights—subscribe as a Global Insider to stay up-to-date with our latest achievements and innovations in the year ahead! #Logenix #GlobalInsider #SupplyChainExcellence #GuineaBissau #ColdChainlogistics #LogisticallyTheBest

Considering annual expenditures of around 20 billion USD, the numerous tragedies caused by counterfeiting, the devastating impact of Covid-19, and the availability of local resources, what is Africa waiting for to develop a world-class pharmaceutical industry? #CAVIE #IntelligenceEconomique #MarchésAfricain #DueDiligence

Regulatory Update 🚨 Two major Indian pharmaceutical companies, Sun Pharma and Dr. Reddy's Laboratories, are recalling products in the US market due to manufacturing issues. Sun Pharma is recalling an eye medication (Xelpros) due to the presence of particles, while Dr. Reddy's is recalling an immunosuppressant medication (Sirolimus) due to impurity concerns. Both recalls are classified as Class III, meaning the products are unlikely to cause serious health problems so, what is Class III recall??? Let's understand the different classes of recalls by USFDA #USFDA #Regulatory #Pharma

📢 Happening Today! Our Board Member & VP Medicines for Europe, Elisabeth Stampa will speak at the European Parliament SANT Committee public hearing on the EU’s growing dependence on imported Active Pharmaceutical Ingredients (APIs). 📅 January 29 | 15:00 CET The EU faces a critical challenge in securing its #supply of essential medicines, with most APIs and finished products imported from Asia. This dependency has weakened Europe’s ability to manufacture key pharmaceuticals, posing a potential risk to public health. 🔹 How can we rebuild robust & resilient medicine supply chains in #Europe? 🔹 Why do we need an EU Critical Medicines Act to address #shortages & support local production? Join the conversation: https://lnkd.in/degvvC5r

📌Our Vice-President Elisabeth Stampa will participate in the European Parliament SANT Committee public hearing, as part of the panel focused on the overreliance on imports of Active Pharmaceutical Ingredients (APIs). 📅 On January 29, we will discuss the challenges of production shifting and the economic viability of off-patent medicines. To achieve its Open Strategic Autonomy, the EU needs a #CriticalMedicinesAct, that includes: 🔹 Investing in building robust & resilient critical medicines supply chains 🔹 Reforming the off-patent medicines market to address shortages ➡️ Stay tuned for more info: https://buff.ly/4hruF4e #EUCriticalHealth

December 9, 2024, Mumbai: Leading the pharmaceutical sector globally, SUPRIYA LIFESCIENCE LIMITED, strengthened its position in foreign markets by achieving two noteworthy milestones. The business has received permission from ANVISA, Brazil's health authorities. Read More : - https://lnkd.in/gBZRSwk6 #SupriyaLifeScience #hydrocloride #Technicalupdate #indiantechnicaltextiles #lifesciences

🚨𝐏𝐮𝐛𝐥𝐢𝐜 𝐩𝐚𝐫𝐭𝐬 𝐨𝐟 𝐁𝐞𝐥𝐠𝐢𝐚𝐧 𝐌𝐚𝐧𝐚𝐠𝐞𝐝 𝐄𝐧𝐭𝐫𝐲 𝐀𝐠𝐫𝐞𝐞𝐦𝐞𝐧𝐭𝐬 (𝐌𝐄𝐀𝐬) 𝐧𝐨𝐰 𝐩𝐮𝐛𝐥𝐢𝐜𝐥𝐲 𝐚𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞 💊 It wasn't too long ago that we wrote an article about how the practice of MEAs, whereby a pharmaceutical company enters into an agreement with the government for the temporary reimbursement of a new drug, was criticized for its confidential nature. It seems the NIHDI 🇧🇪 has heeded this criticism, reason why it recently launched a 𝐰𝐞𝐛 𝐩𝐨𝐫𝐭𝐚𝐥 𝐯𝐢𝐚 𝐰𝐡𝐢𝐜𝐡 𝐲𝐨𝐮 𝐜𝐚𝐧 𝐚𝐜𝐜𝐞𝐬𝐬 𝐭𝐡𝐞 𝐩𝐮𝐛𝐥𝐢𝐜 𝐩𝐚𝐫𝐭𝐬 𝐨𝐟 𝐭𝐡𝐞 𝐌𝐄𝐀𝐬 𝐭𝐡𝐞 𝐍𝐈𝐇𝐃𝐈 𝐜𝐨𝐧𝐜𝐥𝐮𝐝𝐞𝐬. 👉 I'm not overstating when I'm saying that this is really quite the milestone which, among other things, will allow pharmaceutical companies to better prepare their future reimbursement files & MEA negotiations, but will also imply a risk as certain information will now indeed be publicly disclosed. Check it out! Yescarta™️, Zolgensma™️, it's all there! 🔗 𝐖𝐞𝐛 𝐩𝐨𝐫𝐭𝐚𝐥: https://lnkd.in/g3DtJEe9 📝 𝐏𝐫𝐞𝐯𝐢𝐨𝐮𝐬 𝐚𝐫𝐭𝐢𝐜𝐥𝐞: https://lnkd.in/gWJQCGgN #LifeSciences #MEAs #PricingAndReimbursement #Pharmaceuticals #DLAPiper

⭐️🏥 Episode 3 of Legacy Lessons: Ranbaxy's Journey 🌡️ From humble beginnings in Amritsar in 1961, Ranbaxy swiftly rose to become a global pharmaceutical giant, operating in over 120 countries by the 1990s. However, regulatory challenges in the 2000s tarnished its reputation, culminating in its acquisition by Sun Pharmaceutical Industries in 2014. Ranbaxy's story underscores the vital lessons of regulatory compliance and ethical standards in the pharmaceutical sector. 📈 #Ranbaxy #PharmaceuticalIndustry #LegacyLessons #BusinessHistory #GlobalExpansion #RegulatoryCompliance #EthicalStandards #SunPharma #PharmaGiant #CorporateAcquisition #BusinessJourney #IndustryChallenges #PharmaNews #HealthcareSector #CorporateEthics #BusinessLessons #ManagementLessons #IndustryInsights #PharmaLeadership #ComplianceMatters #HealthcareCompliance #BusinessAcquisition #StrategicDecisions #CorporateGrowth #BusinessSuccess #SEC